Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 inhibitor BIIB122 in participants with LRRK2-associated Parkinson’s disease. LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson’s disease by targeting underlying lysosomal dysfunction implicated in this disease. “We are thrilled to initiate this study and broaden our efforts in evaluating BIIB122 as a potential treatment for people living with Parkinson’s disease related to LRRK2 mutations,” said Carole Ho, M.D., Chief Medical Officer at Denali. “We look forward to continued collaboration with the Parkinson’s community as we aim to generate biomarker and safety data to inform how LRRK2 inhibition may have an impact on the course of this disease.”